Sanofi[SNY] stock saw a move by 0.62% on Thursday, touching 1.58 million. Based on the recent volume, Sanofi stock traders appear to be active. The most recent trading volume of SNY shares recorded 2.53B shares, which represents the daily volume of traded shares. Analysts estimates state that Sanofi [SNY] stock could reach median target price of N/A.

Sanofi [SNY] stock additionally went up by +0.28% in the period of the 7 days, recording a gain in performance by 1.16% in the last 30 days. The yearly more of SNY stock is set at 1.93% by far, with shares price recording returns by 9.41% in the latest quarter. Over the past six months, SNY shares showcased 10.68% increase. SNY saw -3.60% change opposing the low price in the last 12 months, also recording 14.40% compared to high within the same period of time.

Sanofi [NASDAQ:SNY]: Analyst Rating and Earnings

Its stock price has been found in the range of 40.00 to 47.47. This is compared to its latest closing price of $45.48.

Keep on the lookout for this organization’s next scheduled financial results, which are expected to be made public on Thu 6 Feb (In 90 Days).

Fundamental Analysis of Sanofi [SNY]

Now let’s turn to look at profitability: with a current Operating Margin for Sanofi [SNY] sitting at +14.74 and its Gross Margin at +60.18, this company’s Net Margin is now 10.70%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.

This company’s Return on Total Capital is 6.45, and its Return on Invested Capital has reached 5.00%. Its Return on Equity is 7.39, and its Return on Assets is 4.09. These metrics suggest that this Sanofi does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organization’s capital structure, Sanofi [SNY] has generated a Total

Debt to Total Equity ratio of 41.85. Similarly, its Total Debt to Total Capital is 29.50, while its Total Debt to Total Assets stands at 22.12. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 10.33, and its Long-Term Debt to Total Capital is 37.38.

What about valuation? This company’s Enterprise Value to EBITDA is 14.03 and its Total Debt to EBITDA Value is 2.88. The Enterprise Value to Sales for this firm is now 3.39, and its Total Debt to Enterprise Value stands at 0.22. Sanofi [SNY] has a Price to Book Ratio of 1.60, a Price to Cash Flow Ratio of 17.12 and P/E Ratio of 27.94. These metrics show that this company has a mixed appeal, and ROI could be a gain or a loss.

Shifting the focus to workforce efficiency, Sanofi [SNY] earns $330,656 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 3.82 and its Total Asset Turnover is 0.33. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 0.98 and its Current Ratio is 1.41. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Sanofi [SNY] has 2.53B shares outstanding, amounting to a total market cap of $114.99B. Its stock price has been found in the range of 40.00 to 47.47. At its current price, it has moved down by -3.60% from its 52-week high, and it has moved up 14.40% from its 52-week low.

This stock’s Beta value is currently 0.62, which indicates that it is 0.90% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 51.31. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is Sanofi [SNY] a Reliable Buy?

Shares of Sanofi [SNY], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.